These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Joseph J; Rodvold KA Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158 [TBL] [Abstract][Full Text] [Related]
5. [Available carbapenems: Properties and differences]. Martínez MJ; García MI; Sánchez EG; Sánchez JE Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931 [TBL] [Abstract][Full Text] [Related]
6. [The role of carbapenems in the treatment of nosocomial infection]. Martínez Lacasa J; Garau J Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():78-85. PubMed ID: 9410075 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ertapenem: review of recent studies. Wexler HM J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179 [TBL] [Abstract][Full Text] [Related]
8. Carbapenems: a potent class of antibiotics. Nicolau DP Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336 [TBL] [Abstract][Full Text] [Related]
9. Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction. Goldstein EJ J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii5-6. PubMed ID: 15228047 [No Abstract] [Full Text] [Related]
10. Empiric treatment of nosocomial intra-abdominal infections: a focus on the carbapenems. Tellado JM; Wilson SE Surg Infect (Larchmt); 2005; 6(3):329-43. PubMed ID: 16201943 [TBL] [Abstract][Full Text] [Related]
11. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553 [TBL] [Abstract][Full Text] [Related]
12. Doripenem: position in clinical practice. Dedhia HV; McKnight R Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791 [TBL] [Abstract][Full Text] [Related]
14. Changing role of carbapenems in the treatment of lower respiratory tract infections. Lode H; Hamacher J; Eller J; Schaberg T Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Moczygemba LR; Frei CR; Burgess DS Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692 [TBL] [Abstract][Full Text] [Related]
16. Properties and potential of ertapenem. Livermore DM; Sefton AM; Scott GM J Antimicrob Chemother; 2003 Sep; 52(3):331-44. PubMed ID: 12917243 [TBL] [Abstract][Full Text] [Related]
18. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. Calandra GB; Hesney M; Brown KR Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144 [TBL] [Abstract][Full Text] [Related]
19. The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection. Powell LL; Wilson SE Surg Infect (Larchmt); 2000; 1(1):57-63. PubMed ID: 12594910 [TBL] [Abstract][Full Text] [Related]
20. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. Italian Intramuscular Meropenem Study Group. Romanelli G; Cravarezza P J Antimicrob Chemother; 1995 Jul; 36 Suppl A():109-19. PubMed ID: 8543487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]